On October 20, 2022 Asymchem (stock code: 002821.SZ), a leading global contract development and manufacturing service provider, and AUM Biosciences (AUM), a global clinical stage biotech company, focused on discovering, acquiring and developing next generation targeted oncology therapeutics, reported the completion of their first GMP production campaign of AUM601 (Press release, AUM BioSciences, OCT 20, 2022, View Source [SID1234622250]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Earlier this year, Asymchem and AUM Biosciences announced the two companies would collaborate on process development and clinical and commercial production of AUM 601, a highly selective oral small molecule inhibitor of the tropomyosin receptor kinase (TRK) for treating rare cancers.

The partnership resulted in 10 kg GMP bulk drug substance of AUM 601, which will be used to supply Phase II clinical trials. AUM 601 has shown potent in vitro and in vivo anti-tumor activities against tumors harboring NTRK fusion.

"Through our collaboration with Asymchem, we were able to develop a more robust manufacturing process for AUM 601 by utilizing affordable and safe reagents that enabled us to improve yield and quality. The promising data further justifies the advancement of AUM601 into Phase II clinical trials," said Vishal Doshi CEO, AUM Biosciences. "Asymchem surpassed our expectations and incorporated innovative ideas and development into the process, allowing us to further our work in transforming the oncology therapeutics market, and addressing unmet needs of patients."

The successful outcome of this collaboration is a testament to both Asymchem’s and AUM’s commitment to quality and excellence in drug development. "With Asymchem’s world-class CDMO service and AUM’s cutting-edge cancer research, together, we are poised to make a significant difference in the lives of cancer patients worldwide," added Elut Hsu, President of Asymchem, Inc.